Oncolytics Biotech (ONCY) Free Cash Flow (2009 - 2025)

Oncolytics Biotech (ONCY) has 17 years of Free Cash Flow data on file, last reported at -$20.1 million in Q4 2025.

• On a quarterly basis, Free Cash Flow fell 258.03% year-over-year to -$20.1 million in Q4 2025; TTM through Dec 2025 was -$33.4 million, a 71.19% decrease from a year earlier, with the FY2025 full-year figure at -$20.1 million, down 3.06% from the prior year.
• Free Cash Flow for Q4 2025 stood at -$20.1 million, down from -$4.8 million in the prior quarter.
• Over the last five years, Free Cash Flow for ONCY reached as high as -$2.8 million in Q3 2021 and fell as low as -$20.1 million in Q4 2025.
• Historically, Free Cash Flow has averaged -$5.5 million across 5 years, with a median of -$4.9 million in 2024.
• Across the five-year window, Free Cash Flow soared 38.84% in 2021 and slumped 258.03% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$5.4 million in 2021, then climbed by 19.26% to -$4.4 million in 2022, then fell by 2.74% to -$4.5 million in 2023, then retreated by 24.83% to -$5.6 million in 2024, then slumped by 258.03% to -$20.1 million in 2025.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$20.1 million in Q4 2025, -$4.8 million in Q3 2025, and -$3.9 million in Q2 2025.